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Abstract
Myo-inositol (MI) supplementation in women with polycystic ovary syndrome (PCOS) 
has been evaluated over the last years. Many hormonal and reproductive impairments 
associated with this disorder seem relieved by the supplement. The objective of the 
meta-analysis was to assess the effects of MI alone or combined with d-chiro-inositol 
(DCI) on the endocrine and metabolic abnormalities of women with PCOS. Literature 
was retrieved from selected databases, MEDLINE, EMBASE, PubMed and Research Gate 
(up to November 2016). Only randomized controlled trials (RCTs) investigating the 
effects of MI alone or combined with dCI were reviewed. Nine RCTs involving 247 cases 
and 249 controls were included. Significant decreases in fasting insulin (SMD = 
 −1.021 µU/mL, 95% CI: −1.791 to −0.251, P = 0.009) and homeostasis model assessment 
(HOMA) index (SMD = −0.585, 95% CI: −1.145 to −0.025, P = 0.041) were identified after 
MI supplementation. The trial sequential analysis of insulin meta-analysis illustrates that 
the cumulative z-curve crossed the monitoring boundary, providing firm evidence of the 
intervention effect. A slight trend toward a reduction of testosterone concentration by 
MI with respect to controls was found (SMD = −0.49, 95% CI: −1.072 to 0.092, P = 0.099), 
whereas androstenedione levels remained unaffected. Throughout a subgroup’s meta-
analysis, a significant increase in serum SHBG was observed only in those studies where 
MI was administered for at least 24 weeks (SMD = 0.425 nmol/L, 95% CI: 0.050–0.801, 
P = 0.026). These results highlight the beneficial effect of MI in improving the metabolic 
profile of women with PCOS, concomitantly reducing their hyperandrogenism.
Introduction
Myo-inositol (MI) is one stereoisomer of a C6 sugar alcohol 
that belongs to the inositol family (1). It is the precursor 
of inositol triphosphate, acting as an intracellular second 
messenger and regulating a number of hormones such 
as thyroid-stimulating hormone, follicle-stimulating 
hormone (FSH) and insulin (2).
MI and d-chiro-inositol (DCI), another stereoisomeric 
form of inositol, balance in different ways some metabolic 
deregulations concurring with insulin resistance (IR) (3): 
MI-derived phosphoinositol-3-phosphate (PIP3) enhances 
glucose transport inside the cells through the stimulation 
of GLUT4 translocation to the cell membrane. Its 
derivative inositolphosphoglycan (MI-IPG) plays a pivotal 
role in downregulating the release of free fatty acids (FFA) 
from adipose tissues, hindering the enzyme adenylate 
cyclase. Indeed, FFA are known to reduce glucose 
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disposal, causing IR and increased triglyceride synthesis. 
DCI upregulates pyruvate dehydrogenase leading to 
the production of ATP by the Krebs’ cycle. MI and DCI 
promote glycogen synthase, inducing glucose conversion 
to glycogen stored inside cells. MI modulates the 
activation of glucose transporters and glucose utilization, 
and glycogen synthesis takes place under the control of 
DCI. This molecule on the ovary regulates the insulin-
induced androgen synthesis, whereas MI regulates glucose 
uptake and FSH signaling (1).
In view of its recognized insulin-sensitizing activity, 
MI has been used to prevent and/or treat a number of 
metabolic disorders related to IR, such as the metabolic 
syndrome (4, 5), gestational diabetes mellitus (6, 7, 8, 9, 
10) and the polycystic ovary syndrome (PCOS) (11, 12, 13).
PCOS is a heterogeneous endocrine, reproductive 
and metabolic disorder, affecting at least 5–10% of the 
total population of reproductive-age women, worldwide 
(14). Independently of body habitus (15), women with 
PCOS manifest a 50–70% incidence of IR, resulting 
in a compensatory hyperinsulinemia, which derives 
many of the phenotypic features of this disease. PCOS 
encompasses a broad spectrum of biochemical/clinical 
signs and symptoms such as irregular menstrual cycles, 
polycystic ovaries, acne, overweight, androgen excess 
with consequent hirsutism and as aforementioned IR 
(16, 17). It is also associated with several long-term health 
consequences, including obesity (18, 19), infertility (20), 
obstetric complications (21), type 2 diabetes (22, 23, 24), 
cardiovascular disease (24, 25, 26, 27), psychological 
distress (28) and ostensibly mood disorders (29, 30). 
A meta-analysis also reported the association between 
women with PCOS and cancer of the endometrium and 
ovarian cancer (31).
It is noteworthy that improvement of IR and reduction 
of circulating insulin are key therapeutic targets in PCOS 
(32), enhancing fertility and reducing the lifelong risk for 
type 2 diabetes and early cardiovascular disease. Besides 
metformin, MI is now considered as a further insulin-
sensitizing supplement which could benefit women with 
PCOS (33, 34). Exercises and a healthy nutritional lifestyle 
have widely been gathering attention in the management 
of PCOS. Although robust data should be addressed in 
further investigation, a study showed beneficial effects in 
patients affected by obesity and type 2 diabetes following 
either a Mediterranean or ketogenic diet (35).
While there are numerous uncontrolled reports, the 
effects of supplementation with MI in PCOS have also been 
evaluated in randomized controlled trials (RCTs). A protocol 
critically reviewing the existing literature has been 
published within the Cochrane Reviews (36). The present 
meta-analysis would identify RCTs of supplementation 
with MI alone or combined with DCI in PCOS, with 
the aim to assess the effectiveness of such treatments in 
restoring the metabolic and endocrine profiles.
Materials and methods
Search strategy and data sources
We performed a literature search of MEDLINE, EMBASE, 
PubMed and Research Gate for studies published in any 
language up to November 2016. We used the following 
combination of medical subject headings, terms and free 
text words: ‘inositol’, ‘MI’, ‘DCI’, ‘PCOS’ and ‘IR’. Only 
RCTs evaluating the supplementation of MI alone or in 
association with DCI in women with PCOS were eligible. 
In addition, reference lists of published reviews were 
reviewed in order to identify additional eligible studies. 
We followed the PRISMA checklist for meta-analysis (38).
Inclusion and exclusion criteria
Articles were critically reviewed for their eligibility in the 
meta-analysis by the two of us (B O and F F). Among all the 
collected articles, RCTs were identified by reading titles, 
abstracts and study design to select relevant studies for 
inclusion/exclusion criteria. Inclusion criteria restricted 
the search to: (a) the population of interest was women with 
PCOS, (b) the intervention was MI with or without DCI, 
(c) assessment of fasting insulin concentrations, HOMA 
index, testosterone, androstenedione and/or sex hormone-
binding globulin (SHBG) plasma levels. Exclusion criteria 
were: (a) articles describing MI treatments in combination 
with other drugs/supplements, (b) duplicate publications, 
and duplicates on different database, (c) review papers 
and (d) animal or cell culture studies.
Outcomes of interest
Primary outcomes: fasting insulin concentrations. 
Secondary outcomes: HOMA index, testosterone, 
androstenedione and SHBG plasma levels.
Data extraction and quality evaluation
The following data were extracted from the full text of 
selected studies and cross-checked by two researchers 
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(B O and F F): general characteristics of the study (first 
author’s name, country where the study was conducted, 
study design, number of cases and controls, body mass 
index, inclusion/exclusion criteria, lifestyle changes, 
type and duration of treatment) and results (means 
and s.d./s.e. for each outcome after intervention from 
treatment vs control). The quality of reports was 
evaluated according to the methods recommended by the 
Cochrane Handbook 5.0.2. (37), including assessments 
of the randomization process, allocation concealment, 
blinding, selection criteria, baseline characters and 
withdrawal/dropouts.
Statistical analysis
The effect size was measured as the standardized mean 
difference (SMD) obtained as Hedges’ g. An SMD 
less than 0 was considered as a positive size effect for 
outcomes, such as fasting serum insulin, HOMA and 
serum testosterone and androstenedione concentrations; 
an SMD greater than 0 was considered as a positive size 
effect for the serum SHBG outcome. The heterogeneity 
analysis of intervention was performed by the Cochran’s 
Q test and the I2 statistic, using a P value = 0.10. In order 
to account for heterogeneity across studies, the Der 
Simonian and Laird random effect model was used to 
obtain the pooled estimates and their 95% confidence 
intervals (CIs). To examine a potential source of 
variation, subgroup meta-analyses were performed 
according to treatment duration, i.e. 12–16  weeks or 
24  weeks. Forest plots were used to visually show the 
results of the analyses performed. Meta-analysis was 
evaluated by the use of Stata Statistical Software: Release 
12 (College Station, TX, USA: StataCorp LP). Results 
were considered statistically significant when the two-
sided P value was <0.05.
Trial sequential analysis (TSA)
The TSA was performed for the insulin outcome in order 
to confirm the result obtained in the traditional meta-
analysis. The cumulative z-curve was calculated with 
a random effect model and the type I error (α) was set 
as 5% with a power of 80%. The sequential monitoring 
boundaries were based on the O’Brien Flaming type alpha 
spending function and the heterogeneity correction was 
model-variance-based. The analysis was conducted with 
the use of TSA software 0.9.5.5 Beta (Copenhagen Trial 
Unit, Copenhagen, Denmark).
Results
Literature search and characteristics of 
included studies
The flow diagram of the meta-analysis is presented in 
Fig. 1 (38). In the initial search, 104 potentially relevant 
articles were identified, and 94 studies remained after 
removing duplicates. Through a preliminary screening, 
76 records were excluded because they did not meet the 
inclusion/exclusion criteria. The remaining 18 articles 
were assessed for eligibility, and 9 articles which met 
the criteria were finally included in the meta-analysis. 
Studies were excluded for several reasons including (a) 
data of the outcome were unavailable or not expressed 
in the numerical form (39), (b) patients were treated with 
MI combined with other molecules such as multivitamin 
complex (40), lactoferrin and bromelin (41) or oral 
contraceptives pills (OCPs) (42), (c) menopausal women 
with metabolic syndrome (4, 5) and (d) the study was a 
non-randomized design (43, 44, 45).
Characteristics of the included studies are 
summarized in Table 1. Studies were conducted in Italy 
(46, 47, 48, 49, 50, 51, 52), Georgia (53) and Turkey (54) 
and were published between 2007 and 2016. Treatments 
Records idenfied through 
database searching
(n = 102)
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
fi
ca
o
n
Addional records idenfied 
through other sources
(n = 2)
Records aer duplicates removed
(n = 94)
Records screened
(n = 94)
Records excluded
(n = 76)
Full-text arcles assessed 
for eligibility
(n = 18)
Full-text arcles excluded, 
with reasons
(n = 9)
Studies included in 
qualitave synthesis
(n = 9)
Studies included in 
quantave synthesis 
(meta-analysis)
(n = 9)
Figure 1
PRISMA (preferred reporting items for systematic reviews and meta-
analyses) flow diagram of study selection (38). Reproduced under the 
terms of the Creative Commons Attribution License from Moher D, 
Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. 
PLoS Medicine 2009 6 e1000097. (doi:10.1371/journal.pmed1000097)
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administered were MI + folic acid (FA) vs FA (46, 47, 48, 49), 
MI + FA vs DCI + FA (50), MI + DCI vs MI (51), MI + DCI + FA 
vs FA (52), and MI + FA vs OCPs (53, 54). The daily dose 
of MI supplementation ranged from 1.1 g to 4 g, and the 
durations of treatment ranged from 12 to 24 weeks. Either 
Rotterdam (55) or Adams and coworkers diagnostic criteria 
(56) were applied for the diagnosis of PCOS. The overall 
methodological study quality is summarized in Table 2.
The meta-analysis
In the nine selected studies, a total of 247 women with PCOS 
received MI alone or combined with FA or DCI, and 249 
women received FA or other treatments (i.e. DCI, OCPs). 
The overall SMD estimated from seven studies showed 
a significant decrease in fasting insulin in PCOS women 
who received MI compared to those who received FA or 
other treatments (SMD = −1.021 µU/mL, 95% CI: −1.791 
to −0.251, P = 0.009) (Fig. 2). Considerable heterogeneity 
among studies was found (Q = 63.85, df = 6, I2 = 90.6%, 
P < 0.001). Evidence of an MI effect was also identified 
for the HOMA index which decreased with treatment 
in the MI group compared to controls (SMD = −0.585, 
95% CI: −1.145 to −0.025, P = 0.041) (Fig. 3). Again, high 
heterogeneity across studies was found (Q = 37.84, df = 6, 
I2 = 84.1%, P < 0.001).
Similarly, seven trials reporting the effect of MI on 
serum testosterone revealed substantial heterogeneity 
among studies (Q = 37.65, df = 6, I2 = 84.1%, P < 0.001) 
(Fig. 4). A slight trend toward a reduction of testosterone 
Table 2 Quality assessment of included trials.
 
 
Study
 
 
Randomization
 
Allocation 
concealment
 
 
Blinding
Selection 
criteria 
described
 
Comparable 
baseline
 
Withdrawal dropout 
described
Genazzani et al. (48) M Unclear N Y Y Unclear
Costantino et al. (47) M Unclear Y, double-blind Y Y Unclear
Gerli et al. (49) Y, computer-generated Unclear Y, double-blind Y Y Y
Artini et al. (46) Y, computer-generated Y, sealed 
numbered 
envelopes
Unclear Y Y Y
Pizzo et al. (50) M Unclear Y, double-blind Y Y Unclear
Pkhaladze et al. (53) M N N Y Y Unclear
Ozay et al. (54) Y Unclear N Y Y M
Nordio and Proietti (51) M N N Y Y Unclear
Benelli et al. (52) M Unclear N Y Y Unclear
Evaluation according to the methods recommended by the Cochrane Handbook 5.0.2 (37).
M, the method was mentioned, but there was not detailed description; N, the method was not used in the study; Unclear, no relevant information was 
found in the study; Y, the method was reported with detailed description.
Figure 2
Forest plot showing effect sizes (standardized mean difference (SMD), 95% confidence interval (CI)) for fasting insulin in women with PCOS.
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concentrations by MI with respect to controls was found 
(SMD = −0.482, 95% CI: −1.052 to 0.088, P = 0.097) 
(Fig. 4). Conversely, no difference between treatments was 
observed either for androstenedione (SMD = −0.097 ng/mL, 
95% CI: −0.499 to 0.305, P = 0.635) (Fig. 5) or SHBG levels 
(SMD = 0.166 nmol/L, 95% CI: −0.247 to 0.580, P = 0.430) 
(Fig. 6).
A subgroup analysis was undertaken stratifying 
the studies by treatment duration. Treatment of MI 
up to 16  weeks had no significant effect on SHBG 
levels compared to controls (SMD = −0.016 nmol/L, 
95% CI: −0.621 to 0.589, P = 0.958) (Fig.  6). However, 
MI supplementation up to 24 weeks revealed a significant 
increase in SHBG levels compared to other treatments 
(SMD = 0.418 nmol/L, 95% CI: 0.049–0.786, P = 0.026) 
(Fig. 6). After stratification, heterogeneity was substantial 
among RCTs lasting 12–16  weeks (Q = 17.98, df = 3, 
I2 = 83.3%, P < 0.001), whereas it was much lesser among 
those of longer duration (Q = 2.49, df = 2, I2 = 19.6%, 
P = 0.288).
Results of TSA
The z-curve after the fourth trial crossed the sequential 
monitoring boundary providing firm evidence of an effect 
of MI on fasting insulin compared to controls (Fig. 7).
Figure 3
Forest plots showing effect sizes (SMD) for HOMA in women with PCOS.
Figure 4
Forest plots showing effect sizes (SMD) for testosterone in women with PCOS.
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Discussion
The current meta-analysis highlights the beneficial effect 
of inositol(s) supplementation, namely MI in improving 
the metabolic profile of PCOS patients. Indeed, grouping 
the nine eligible studies, results revealed differences 
in the treatment effect on fasting serum insulin and 
on the HOMA index, both of them being significantly 
decreased after MI supplementation. In this study, 
through the use of TSA, it was illustrated that the 
findings on the primary outcome are conclusive. Less 
clear changes could be demonstrated on androgenic 
hormones. Circulating androstenedione levels were 
unaffected by MI, while a trend toward a decrease of total 
testosterone occurred. Moreover, a significant increase of 
serum SHBG compared to other treatments was reported 
only in those trials which supplemented inositol(s) for at 
least 24 weeks.
These findings were limited by differences in the 
inclusion criteria of the studies, non-uniform definitions 
of PCOS and diversity in the components of the 
intervention such as dose and duration. All these factors 
therefore explain the high heterogeneity statistically 
demonstrated along with the effects.
Figure 5
Forest plots showing effect sizes (SMD) for androstenedione in women with PCOS.
Figure 6
Subgroup meta-analysis for SHBG stratifying the studies by treatment duration (MI up to 16 weeks or 24 weeks).
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MI is the most abundant form of inositol in humans. 
It can turn into various derivatives through either 
epimerization, phosphorylation or methylation of its 
hydroxyl groups. The NAD/NADH epimerase, an insulin-
dependent enzyme, converts MI into DCI, depending on 
the specific needs of the tissue for these two molecules 
(57, 58). Indeed, different tissues have a typical conversion 
rate and consequently show different MI/DCI ratios (for 
instance, in the ovary, it is 100:1) (59). The epimerase 
activity is reduced in the tissues of type 2 diabetic 
rats (60). There is evidence that MI to DCI conversion rate 
is impaired in PCOS patients due to IR; this aberration 
is exacerbated when having first-degree diabetic relatives 
(41, 58). The pathology itself or the familial predisposition 
negatively affects the epimerase activity, thus increasing IR 
and compensatory hyperinsulinaemia (61). Indeed, lower 
levels of DCI reduce the availability of IPGs triggering 
the onset of IR (62, 63). Baillargeon and coworkers have 
demonstrated an increase of DCI urinary excretion in PCOS 
women compared to normal controls accompanied by a 
decrease of plasma DCI concentrations (11, 64). However, 
no difference was found in MI concentration (64). 
It has been shown how administration of small DCI 
doses can restore insulin sensitivity and improve the 
hormonal pattern in obese hyperinsulinemic PCOS 
patients and even more if having diabetic relatives 
(41, 61). This specific effect might be due to its recognized 
insulin-sensitizing action at the systemic level. Therefore, 
the administration of DCI along with MI might have a 
greater beneficial effect when the epimerase conversion 
is impaired in insulin-resistant tissues to compensate 
for the low endogenous DCI synthesis and its excessive 
urinary excretion, as well as ensuring the required tissue 
content of DCI derivatives. Ovaries, differently from 
other tissues, never become insulin-resistant (65, 66, 67). 
From this observation, it has been speculated that PCOS 
patients with hyperinsulinemia may have an accelerated 
MI to DCI epimerization, resulting in an overproduction 
of DCI and consequently an MI deficiency in the ovary 
(68, 69). The well-known ‘DCI paradox’ hypothesizes 
that only MI has a beneficial effect on the ovary (70). 
This theory has been later confirmed by a recent study 
showing that the oocyte quality and ovarian response 
have been progressively worsened by the increased dosage 
of DCI (71). Therefore, DCI supplementation alone is 
not recommendable for several reasons: (a) high doses 
of DCI/day have been considered toxic to ovaries and 
oocyte maturation (71); (b) DCI is not converted into MI; 
therefore, the specific action exerted by the last one would 
be lost; (c) MI and MI-IPG deficiencies are correlated with 
many IR conditions. Since MI competes with glucose 
for cellular transporters, a low MI intracellular uptake 
and increased urinary loss of MI may lead to high blood 
glucose levels. It can be supposed that adequate MI intake 
and body storages might derive the epimerase by substrate 
mass action inducing DCI synthesis. This agrees with the 
clinical evidence that reported the beneficial effect exerted 
by MI and DCI combined at 40:1 ratio in PCOS patients 
(51, 52). Further investigations might be required as also 
suggested by other researchers (72).
Hyperinsulinemic IR has been shown to play a 
pivotal pathogenic role in the endocrine and metabolic 
Figure 7
Trial sequential analysis on insulin outcome.
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abnormalities of PCOS (73, 74). The improvement of 
insulin sensitivity and the reduction of serum insulin 
demonstrated by MI supply are of paramount importance 
for ameliorating the clinical features of women with 
PCOS (75). The CIs for the selected studies were relatively 
narrow and displayed effect sizes that may be clinically 
relevant. These findings, therefore, support the practice 
of treating PCOS women with MI, either alone or in 
combination with DCI, to improve their endocrine and 
metabolic profiles.
Treatment duration seems crucial, as far as androgen 
profile is concerned. This agrees with the previous 
observation on acne, whose improvement with MI 
required at least 6 months supplementation (45).
Indeed, insulin affects the androgenic state not 
only directly by interfering with metabolism of ovarian 
androgens, but also indirectly by decreasing circulating 
SHBG levels (32). SHBG is a protein that binds to 
testosterone, making it unavailable to target tissues. 
Higher levels of SHBG lead to lower bioavailability of 
testosterone, thus minimizing the hyperandrogenic 
features. Furthermore, SHBG appears to be a potentially 
valuable marker of IR in PCOS (76). Interventions 
improving insulin sensitivity and reducing circulating 
insulin, such as metformin, troglitazone and pioglitazone, 
have been shown to reduce circulating testosterone and 
increase serum SHBG levels (77, 78, 79). Clinical studies 
suggested that metformin, used as an antidiabetic drug, 
may improve insulin sensitivity in obese women with 
PCOS by restoring an inositol-based signaling (61, 80). 
Nonetheless, these drugs have been reported to be 
associated with adverse effects (81). Indeed, metformin, 
the most common insulin-sensitizing agent for PCOS (82, 
83, 84, 85, 86), significantly induces nausea, abdominal 
distress and diarrhea, thereby reducing patients’ 
compliance (87, 88). MI is generally well tolerated across 
the range of therapeutic dosages (89), with the exception 
of minor side effects reported at higher concentration. 
Interestingly, in this meta-analysis, the tolerability profile 
of MI is considered to be quite agreeable. Among the 
studies, only Gerli and coworkers reported side effects on 
the dosage regimen commonly used (49).
The growing interest toward the clinical effects 
of inositols is witnessed by the recent meta-analysis 
which demonstrated how this supplement is effective 
in promoting ovulation in patients with PCOS (90). 
In conclusion, the present meta-analysis of nine RCTs 
revealed that MI alone or combined with DCI improves 
the metabolic profile of women with PCOS, also increasing 
SHBG when supplementation lasted at least 24 weeks.
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